Recent Updates
Recently added Catalysts
PTN

CORPORATE PRESENTATION Corporate Presentation

Monday, November 6, 2006 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CORPORATE PRESENTATION Corporate Presentation CORPORATE PRESENTATION

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~4 mo
High dilution risk
Lead asset
Bremelanotide
Phase 3 · Hypoactive Sexual Desire Disorder

Full Press Release Details

CORPORATE PRESENTATION Corporate Presentation CORPORATE PRESENTATION
ShareAdd on Google
Tags: PTN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Nov 6, 2006

Biotech snapshot

Cash runway
$10M liquidity · $1M/mo burn
~4 mo
High dilution risk
Lead asset
BremelanotidePhase 3
Hypoactive Sexual Desire Disorder →